{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T03:08:19Z","timestamp":1779246499171,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,5,10]],"date-time":"2017-05-10T00:00:00Z","timestamp":1494374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81600143"],"award-info":[{"award-number":["81600143"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Shanghai Science and Technology Committee","doi-asserted-by":"publisher","award":["15YF1403700"],"award-info":[{"award-number":["15YF1403700"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Key Laboratory of Clinical Geriatric Medicine","award":["13DZ2260700"],"award-info":[{"award-number":["13DZ2260700"]}]},{"name":"Shanghai Key Developing Disciplines Program","award":["2015ZB0501"],"award-info":[{"award-number":["2015ZB0501"]}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["EBioMedicine"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.ebiom.2017.04.037","type":"journal-article","created":{"date-parts":[[2017,5,11]],"date-time":"2017-05-11T09:34:38Z","timestamp":1494495278000},"page":"70-78","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6\/STAT3\/PI3K Axis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5102-5158","authenticated-orcid":false,"given":"Jiexian","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kefei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiya","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxian","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youhua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanhui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.ebiom.2017.04.037_bb0005","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3324\/haematol.2009.005835","article-title":"Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia","volume":"94","author":"Aue","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.ebiom.2017.04.037_bb0010","first-page":"23","article-title":"Clinical significance of T-regulatory cells in B-cell non-Hodgkin's lymphoma","volume":"18","author":"Baraka","year":"2011","journal-title":"Egypt J. Immunol."},{"issue":"4","key":"10.1016\/j.ebiom.2017.04.037_bb0015","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Broyl","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ebiom.2017.04.037_bb0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4558","article-title":"Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment","volume":"237","author":"Carbone","year":"2015","journal-title":"J. Pathol."},{"issue":"1","key":"10.1016\/j.ebiom.2017.04.037_bb0025","first-page":"36","article-title":"Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications","volume":"140","author":"Chang","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ebiom.2017.04.037_bb0030","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jaci.2007.08.053","article-title":"Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee","volume":"120","author":"Geha","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.ebiom.2017.04.037_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.critrevonc.2010.09.003","article-title":"Mantle cell lymphoma: the promise of new treatment options","volume":"80","author":"Goy","year":"2011","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"29","key":"10.1016\/j.ebiom.2017.04.037_bb0040","doi-asserted-by":"crossref","first-page":"3688","DOI":"10.1200\/JCO.2013.49.2835","article-title":"Single agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study","volume":"31","author":"Goy","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ebiom.2017.04.037_bb0045","doi-asserted-by":"crossref","first-page":"523842","DOI":"10.1155\/2012\/523842","article-title":"Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent non-Hodgkin's lymphomas","volume":"2012","author":"Gunnellini","year":"2012","journal-title":"Adv. Hematol."},{"issue":"3","key":"10.1016\/j.ebiom.2017.04.037_bb0050","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/j.1365-2141.2009.07626.x","article-title":"Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma","volume":"145","author":"Habermann","year":"2009","journal-title":"Br. J. Haematol."},{"issue":"31","key":"10.1016\/j.ebiom.2017.04.037_bb0055","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1200\/JCO.2014.59.9258","article-title":"Randomized trial of lenalidomide alone versus lenalidomide plus rituximab in patients with recurrent follicular lymphoma: CALGB 50401 (alliance)","volume":"33","author":"Leonard","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.ebiom.2017.04.037_bb0060","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"Suppl. I","key":"10.1016\/j.ebiom.2017.04.037_bb0065","article-title":"CALGB 50803(ALLIANCE): a phase 2 trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma","volume":"31","author":"Martin","year":"2013","journal-title":"Hematol. Oncol."},{"issue":"4","key":"10.1016\/j.ebiom.2017.04.037_bb0070","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.12046","article-title":"Guidelines for the investigation and management of mantle cell lymphoma","volume":"159","author":"McKay","year":"2012","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.ebiom.2017.04.037_bb0075","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3109\/10428194.2014.938333","article-title":"Therapy with bortezomib plus lenalidomide for relapsed\/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501)","volume":"56","author":"Morrison","year":"2014","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.ebiom.2017.04.037_bb0080","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1182\/blood-2010-04-189977","article-title":"Mantle cell lymphoma: biology, pathogenesis and the molecular basis of treatment in the genomic era","volume":"117","author":"P\u00e9rez-Gal\u00e1n","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2017.04.037_bb0085","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1002\/cytob.21109","article-title":"Flow Cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment","volume":"86","author":"Raja","year":"2014","journal-title":"Cytometry B Clin. Cytom."},{"issue":"1","key":"10.1016\/j.ebiom.2017.04.037_bb0090","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/j.1365-2141.2007.06841.x","article-title":"Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo","volume":"140","author":"Reddy","year":"2008","journal-title":"Br. J. Haematol."},{"issue":"9","key":"10.1016\/j.ebiom.2017.04.037_bb0095","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1200\/JCO.2010.31.8907","article-title":"Targeting the interleukin-6\/Jak\/stat pathway in human malignancies","volume":"30","author":"Sansone","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"43","key":"10.1016\/j.ebiom.2017.04.037_bb0100","doi-asserted-by":"crossref","first-page":"30082","DOI":"10.1074\/jbc.M114.591719","article-title":"A signal transducer and activator of transcription 3_nuclear factor \u03baB (Stat3-NF\u03baB) complex is necessary for the expression of fascin in metastatic breast cancer cells in response to interleukin (IL)-6 and tumor necrosis factor (TNF)-\u03b1","volume":"289","author":"Snyder","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.ebiom.2017.04.037_bb0105","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23176","article-title":"Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management","volume":"87","author":"Vose","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"1","key":"10.1016\/j.ebiom.2017.04.037_bb0110","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0895-3988(09)60019-2","article-title":"Curcumin, a potential inhibitor of up-regulation of TNF-\u03b1 and IL-6 induced by palmitate in 3T3-L1 adipocytes through NF-\u03baB and JNK pathway","volume":"22","author":"Wang","year":"2009","journal-title":"Biomed. Environ. Sci."},{"issue":"30","key":"10.1016\/j.ebiom.2017.04.037_bb0115","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ebiom.2017.04.037_bb0120","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.ebiom.2017.04.037_bb0125","doi-asserted-by":"crossref","first-page":"4650","DOI":"10.1158\/1078-0432.CCR-07-4405","article-title":"Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells","volume":"14","author":"Wu","year":"2008","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ebiom.2017.04.037_bb0130","doi-asserted-by":"crossref","first-page":"416","DOI":"10.3324\/haematol.2011.051813","article-title":"Salvage treatment with lenalidomide and dexamethasone in relapsed\/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers","volume":"97","author":"Zaja","year":"2012","journal-title":"Haematologica"},{"issue":"18","key":"10.1016\/j.ebiom.2017.04.037_bb0135","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","article-title":"Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells","volume":"120","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ebiom.2017.04.037_bb0140","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblon-binding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ebiom.2017.04.037_bb0145","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2012","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ebiom.2017.04.037_bb0150","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/annonc\/mdt366","article-title":"Long-term follow-up of lenalidomide in relapsed\/refractory mantle cell lymphoma: subset analysis of the NHL-003 study","volume":"24","author":"Zinzani","year":"2013","journal-title":"Ann. Oncol."}],"container-title":["EBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417302128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396417302128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T18:46:58Z","timestamp":1762454818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396417302128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":30,"alternative-id":["S2352396417302128"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.04.037","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synergistic Cytotoxicity of Lenalidomide and Dexamethasone in Mantle Cell Lymphoma via Cereblon-dependent Targeting of the IL-6\/STAT3\/PI3K Axis","name":"articletitle","label":"Article Title"},{"value":"EBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2017.04.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}